Pilot Therapeutics Holdings, Inc.  

(Public, OTCMKTS:PLTT)   Watch this stock  
Find more results for L JAMES COSTA�
Jan 25 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol / Avg. 0.00/0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.54
Shares 11.55M
Beta     -
Inst. own 0%

Key stats and ratios

Q2 (Jun '03) 2002
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -179.13% -146.89%
Return on average equity - -
Employees 14 -
CDP Score - -


101 N Chestnut St Ste 102
WINSTON SALEM, NC 27101-4046
United States - Map
+1-336-7252222 (Phone)
+1-302-6555049 (Fax)


Pilot Therapeutics Holdings, Inc. is a holding company for Pilot Therapeutics, Inc. and is a specialty pharmaceutical company. Through lipid profiling and metabolism, the Company has developed a proprietary, lipid and genomic profiling research platform, termed Functional Liponomics. Using Functional Liponomics, the Company is developing novel, branded, therapeutic, pharmaceutical and over-the-counter (OTC) medical food products that are specifically designed to address dysfunctional lipid metabolism in chronic human diseases such as asthma, coronary heart disease, allergic rhinitis, cancer, cystic acne and rheumatoid arthritis. Pilot expects to launch its first product, Airozin, for adults and children regionally in April 2003 and nationally by 2004.

Officers and directors

Terrance L. Little Chairman of the Board
Keith Wakeman President
Ross Consaul Chief Executive Officer
Steven Greenberg Chief Financial Officer
Floyd H. Chilton Ph.D. Chief Technology Officer, Director
Age: 50
Scott Derks Vice President - Operations
John Crain Vice President of Sales, Pilot Therapeutics, Inc.
Age: 61
Jack Voller Vice President - Marketing of Pilot Therapeutics, Inc.
Age: 62
Santo Joseph Costa J.D. Director
Age: 69
James W. Johnston Director
Age: 68